IN RESPONSE: Dr. Potyk states that we did not comment on the effects of perioperative ␤-blockade. On the basis of all the ␤-blocker trials in patients undergoing noncardiac surgery, there is strong evidence that ␤-blockade prevents perioperative MI. Contrary to Dr. Potyk's statement, perioperative ␤-blockade probably increases the risk for death and almost certainly increases the risk for stroke (1, 2) . Our interpretation of these data is that controlling the sympathetic system in the perioperative setting is beneficial, but we need to find a way to do it safely and practically.
Dr. Potyk believes that it is not necessary to monitor perioperative troponin levels in at-risk patients. We disagree for the following reasons. Our data suggest that 5.0% of at-risk patients will have an MI and that 65.3% of these events would have gone undetected without monitoring troponin levels. Patients who have had a perioperative MI without ischemic symptoms have a poor prognosis (a 12.5% mortality rate at 30 days). Although 8.3% of patients had isolated elevation of troponin levels, these elevations represent myocardial injury and carry a poor prognosis. The highest quartile of these elevations was associated with a substantial increase in 30-day mortality (adjusted odds ratio, 2.54 [95% CI, 1.65 to 3.90]).
We have also recently demonstrated that elevated troponin levels (adjusted odds ratio, 6.7 [CI, 4.1 to 10.9]) after surgery independently affect mortality until at least 12 months after surgery (3) . Our data show that many patients with elevated troponin levels and perioperative MI leave the hospital without medications that decrease the risk for major cardiovascular events (for example, acetylsalicylic acid or statins).
Awareness of elevated troponin levels and perioperative MI is necessary for optimum informed decision making in the postoperative period. We agree that it is preferable to prevent a perioperative event than to need to treat it. Continued efforts at evaluating a wide range of strategies are needed.
OBSERVATIONS

Discordant Thymectomy in Identical Twins Concordant for Myasthenia Gravis
Background: Thymectomy is standard therapy for nonthymomatous myasthenia gravis despite the absence of randomized clinical trials (1) . Myasthenia gravis is uncommonly reported in monozygous twins; disease concordance occurs in approximately one third of such identical twin pairs; and treatment for myasthenia gravis, when described, is usually concordant in identical twin pairs (2) .
Objective: To report an 11-year clinical course of a pair of identical twins concordant for generalized acetylcholine receptor antibody-positive nonthymomatous myasthenia gravis in whom only 1 was treated with extended transsternal thymectomy.
Case Report: Twin A was a 19-year-old white woman who presented with an 8-week history of intermittent leg weakness, causing her to fall during activities, such as climbing stairs. On examination, she had moderately severe fatigable proximal muscle weakness and ptosis. Her weakness improved with intravenous edrophonium administration. Initial binding acetylcholine receptor antibody titer was 1.22 nmol/L (normal value, Ͻ0.03 nmol/L). Repetitive 2-Hz nerve (median, ulnar, and facial) stimulation studies demonstrated up to a 16% decremental response. Chest computed tomography showed residual thymic tissue without thymoma. An extended transsternal thymectomy was performed 11 weeks after the onset of symptoms.
Pathologic examination showed thymic tissue with increased lymphoid nodules. The patient's strength normalized approximately 1 month after thymectomy and has remained normal for 11 years. Binding acetylcholine receptor antibody titers have remained elevated to a similar degree. Twin A has not been treated with immunosuppressive therapy. Despite an invariably normal examination, the patient uses occasional low doses of pyridostigmine for subjective fatigue.
Five months after her twin sister had developed initial symptoms of myasthenia gravis, twin B developed ptosis, diplopia, and proximal muscle weakness associated with an upper respiratory infection. On examination, twin B had moderately severe fatigable proximal muscle weakness and ptosis. Her weakness improved with intravenous edrophonium. Initial binding acetylcholine receptor antibody titer was 75.3 nmol/L (normal value, Ͻ0.03 nmol/L). Repetitive 2-Hz nerve (median, ulnar, and facial) stimulation studies demonstrated up to a 12% decremental response. Chest computed tomography showed thymic tissue without thymoma. Twin B declined thymectomy and immunosuppressant therapy and continued to have bilateral ptosis and fatigable muscle weakness that was moderately severe and greater in the proximal muscles than the distal muscles; weakness has been responsive to pyridostigmine therapy. Binding acetylcholine receptor antibody titers have remained similarly elevated over the past 11 years.
Twins A and B had identical human leukocyte antigen typing (A1, A23, B8, B44, C4, DR13, DR17, DQ2, DQ6, DR52), suggesting that they are monozygous twins. Normal serum complement (C3 and C4) levels were reported in both twins. There was no other family history of autoimmune disease. Although acetylcholine receptor antibody titer levels do not correlate with disease severity, twin B had much higher levels at diagnosis (3). Twin A's acetylcholine receptor antibody titer levels did not decrease after thymectomy, but her strength became normal.
Discussion: We report our clinical observation on thymectomy compared with the natural disease history in a single set of identical twins. Compared with untreated twin B, thymectomy in twin A was associated with sustained clinical remission, with no requirement to use immunosuppressive therapy to maintain it. Although most nonrandomized studies suggest that thymectomy is associated with improved outcomes in myasthenia gravis (4), demonstration of clinical efficacy must await the outcome of a prospective, randomized clinical trial (5). Because no immunosuppressive agent was given to twin B, our clinical observation could not be ethically replicated in randomized clinical trial (5).
Treatment of Chronic Hepatitis E in a Patient With HIV Infection
Background: Hepatitis E virus (HEV) infections in immunosuppressed patients can result in chronic hepatitis that rapidly progresses to cirrhosis (1, 2) . When immunosuppressed transplant recipitents are treated with pegylated ␣-interferon and ribavirin, HEV clears and liver histology improves (2) . However, we are not aware of reports about how this therapy works in patients with HIV infection.
Objective: To describe the clinical and laboratory response to antiviral therapy for chronic HEV infection in a patient also infected with HIV.
Case Report: We studied a 48-year-old bisexual male with HIV-1 infection who was chronically infected with HEV genotype 3a and had several years of painful sensory neuropathy of uncertain cause in the lower limbs (3). He had malaise, persistently abnormal liver function tests, and active inflammation and cirrhosis on liver biopsy (Figure) . Before beginning anti-HEV therapy, the patient had an undetectable HIV viral load and a CD4 cell count between 30 and 150 cells/mL for the previous 2 years while receiving combination antiretroviral therapy (abacavir-lamivudine once daily and lopinavir-ritonavir twice daily).
To control the patient's HEV infection, we administered pegylated ␣-interferon; 135 g/wk for 6 months, followed by 6 weeks of pegylated ␣-interferon with ribavirin, 1000 mg/d. We reduced the dose of ribavirin to 500 mg/d for an additional 6 weeks owing to marrow suppression.
Shortly after therapy began, the patient's malaise improved, and his liver function tests became normal. There was a gradual and sustained improvement in his neurologic symptoms. The HEV viral load in plasma and stool declined steadily during the 6-month course of interferon monotherapy, so that at the end of monotherapy, HEV viral load was undetectable in plasma but still detectable in stool at 2.2e
ϩ04 GEq/ mL. After ribavirin was added to therapy, viral load in the stool decreased rapidly. The HEV RNA levels eventually became undetectable and remained largely undetectable over the next 9 months. However, very low levels of HEV RNA (5 to 55 GEq/mL) were detected intermittently in both plasma and stool. A liver biopsy taken 3 months after therapy was completed showed reduced inflammation and fibrosis (Figure) . The patient's CD4 count improved from a pretreatment count of 94 cells/mL (7%) to 270 cells/mL (10%) 6 months after HEV clearance. We detected HEV RNA in cerebrospinal fluid before treatment and at completion of therapy, but not 3 months later.
Discussion: The data show that chronic HEV infection can be successfully treated with interferon and ribavarin therapy when the patient has HIV-1 co-infection, although our patient required a longer period of treatment to achieve viral clearance than has been reported in transplant patients. Clearance of HEV was associated with an improvement in the patient's symptoms, normalization of liver function tests, reduction in inflammation and fibrosis on liver biopsy, and improvement in CD4 cell count. The data also suggest that HEV infection may be associated with peripheral neuropathy (4), which can respond to HEV treatment. In our patient, viral clearance of HEV from cerebrospinal fluid lagged behind viral clearance from serum and stool levels and improvement in neuropathy symptoms, perhaps because of viral "compartmentalization" in different tissue spaces (5). 
